Cancer cells of different origin, when exposed to standard chemo- or target-therapy promptly react through the activation of a common survival pathway centred around the EGFR receptor family member ErbB3 and its downstream signalling elements PI3K and AKT. This evidence concerns the gene AKT1 and cancer.